EEF2K and gastric adenocarcinoma: Compared with cases without eEF2K gene alterations, eEF2K changes are not significantly associated with OS (p = 0.709), DFS (p = 0.908), DSS (p = 0.780), and PFS (p = 0.0755) in patients with OV; OS (P = 0.719), DFS (p = 0.348), DSS (p = 0.209), and PFS (p = 0.343) in patients with STAD; and OS (p = 0.709) and DFS (p = 0.709) in patients with COAD (Fig. 4E).